Conclusions ICI is associated with a high incidence of TE in patients with melanoma; TE is associated with substantial worsening of survival.

http://dx.doi.org/10.1136/jitc-2020-SITC2020.0649

**51**
**NEUROLOGICAL ADVERSE EVENTS ASSOCIATED WITH IMMUNE CHECKPOINT INHIBITORS: OUR EXPERIENCE IN A TERTIARY CARE CENTER**

Pablo Alvarez-Ballesteros*, Javier Buisan-Catevilla, Alvaro Beltrán-Corbellini, Ilgí Corral-Corral, Javier Pozas-Perez, Víctor Albanan-Fernandez,Lucia Sanz-Gomez, Jorge Esteban-Villarubia, Javier TorresJiménez, Jesús Chamorro-Perez, Diana Rosero-Rodríguez, Maria San Román-Gil, Ainara Soria-Rivas. Ramon y Cajal University Hospital, Madrid, Spain

**Background** Immune checkpoint inhibitors (ICIs) have become a revolution in the treatment of many tumoral diseases, resulting in a significant increase in terms of life expectancy and quality of life. Despite these outstanding advances in long-life survival, a new spectrum of adverse events has been developed and is known to be one of the biggest challenges in clinical practice nowadays. Immune-mediated neurotoxicity stands out as a rather unusual complication, but its potentially lethal consequences make the characterization and right management of this adverse event a crucial issue in this field.

**Methods** This is a retrospective study including all the cancer patients that have developed any neurological adverse event related to ICIs treatment, in a period of 4 years (from 2017 to 2020).

**Results** 13 patients were included in the study (8 were treated with anti-PD-1/PD-L1 immunotherapy, 1 with anti-CTLA-4 and 4 with the combination of both strategies). 4 patients developed generalized myasthenia gravis (GMG), 4 immune-mediated encephalitis (IME), 3 immune-related encephalopathy without radiological/analytical evidence of encephalitis, 1 mixed-polyneuropathy, and 1 polymyositis. 3 patients with GMG were seropositive, 3 developed the clinical feature within the first 21 days of immunotherapy treatment and all of them received anti-PD-1/PD-L1 treatment. All patients with IME showed pleocytosis in cerebrospinal fluid, without any data in brain MRI. 12 patients suspended ICIs treatment after the event and were treated with high doses of intravenous corticosteroids. Half of them required treatment with intravenous immunoglobulins. 10 showed total or partial resolution as clinical outcome. However, 4 patients passed away due to toxicity (2 with GMG). In severe cases that precise ICU admission, 4 out of 6 patients (66%) showed a spectacular clinical improvement with complete recovery after early treatment with high doses of methylprednisolone and intravenous immunoglobulins. ICIs withdrawal was sustained indefinitely in all patients, showing a progression-free survival at six-months of 50%. In patients with tumoral diseases that have an indication of treatment with ICIs, the PFS at 6 and 12 months stands at 66%.

**Conclusions** In this series, the majority of neurotoxicity was associated with high incidence of TE in patients with melanoma; TE is associated with substantial worsening of survival.

http://dx.doi.org/10.1136/jitc-2020-SITC2020.0651

**652**
**EARLY OUTCOMES OF AN APP ACUTE CHECKPOINT INHIBITOR (CPI) CARE CLINIC**

Lisa Kottschade*, Casey Fazer, Anna Scheweke. Mayo Clinic, Rochester, MN, USA

**Background** Checkpoint inhibitors continue to be used for a wide variety of oncologic and hematologic indications. Early recognition and intervention is crucial to prevent significant morbidity and/or mortality from immune related adverse events (irAEs). Physicians and APPs outside of hematology/oncology practices are generally not familiar with these types of side effects which may lead to treatment delays, and inappropriate management. We recently identified this as a gap in continuity of care amongst patients undergoing CPI therapy for their malignancy, and therefore developed a CPI acute care outpatient clinic, designed to meet this need.

**Methods** Starting April 2020, we developed an CPI focused clinic led by 3 APPs to provide outpatient irAE management 5 days a week. Three types of needs were identified: acute (within 24 hours), post hospitalization (within 48 hours of discharge), and long term follow-up (high grade irAE).

**Results** From April 24-August 24, 2020 our CPI clinic had a total of 50 visits (30 unique patients). Given that many patients to our practice are from >2 hours away, as well as the constraints of the current pandemic, visits were conducted as in person, video consult (telemedicine), or phone. The most common regimens for patients were PD-1 alone (10), PD-1 + targeted (7), dual CPI (6), PD-1 + chemotherapy, and clinical trial, PD-1 alone, PD-1 + chemotherapy (1 each). The top three types of malignancies seen were melanoma (7), lung (6) and gynecological (4). The most common irAE referral reason was hepatitis (8), diarrhea/colitis (6) and thyroiditis (4). Only three patients (10%) required higher level care (i.e ED or admission) than was able to be provided in the clinic. Twenty-two patients (73%) required steroids as their initial treatment for irAE, with 4 patients (13%) requiring referral to other specialties. Twelve patients (40%) presented with ≥2 irAE’s at the time of being seen in clinic.

**Conclusions** Herein we present early data from an acute care APP led CPI outpatient clinic. Most patients required initiation of steroids for their irAE, however only a small majority required higher level of care and were able to be managed as an outpatient. We acknowledge that while our cohort of patients is small, it does provide early evidence of the utility of a CPI acute care clinic and additional hypothesis generating clinical questions.

**Ethics Approval** This study was approved by the institutional review board at Mayo Clinic.

http://dx.doi.org/10.1136/jitc-2020-SITC2020.0652

**653**
**DASATINIB AS A RAPID PHARMACOLOGICAL ON/OFF SWITCH FOR T CELL BISPECIFIC ANTIBODY-INDUCED T CELL ACTIVATION AND CYTOKINE RELEASE**

1Gabrielle Lederer*, 1Helene Haegel, 1Anneliese Schneider, 2Estelle Mamer Berger, 2Antje Walz, 2Christophe Boetsch, 1Vesna Pulko, 1Cristiano Ferlini, 1Christian Klein. 1Roche Innovation Center Zürich, Schlieren, Switzerland; 2Roche Innovation Center Basel, Basel, Switzerland

**Background** T cell bispecific antibodies (TCBs) are extremely potent T cell engagers, harboring a 2+1 format with one binder to the CD3ε chain and two binders to specific tumor antigens. Crosslinking of CD3 with tumor antigens triggers T cell activation, proliferation and cytokine release, leading to
Abstracts

Background The landscape of cancer treatment has changed drastically since the development of Immune Checkpoint Inhibitors (ICI). ICIs have become the cornerstone to various cancer treatments. The adverse effect (AE) profile of ICI is different than conventional chemotherapy. Nivolumab and pembrolizumab target programmed cell death-1 T-cell receptor, whereas programmed death ligand-1 is targeted by atezolizumab and durvalumab. Easy tolerability and lack of myelo-suppression make immunotherapy an attractive treatment option. Some AEs can be severe, life-threatening, or even fatal (grade III and higher). Much of the data regarding AE profile is from clinical trials. The aim of our study is to review real world single institution AE data on the most commonly utilized ICIs.

Methods We reviewed a total of 229 patient charts who had received pembrolizumab, nivolumab, durvalumab or atezolizumab at Saint Francis Hospital in Hartford, CT, USA.

Conclusions Taken together, we provide evidence for the use of dasatinib as a pharmacological on/off switch to mitigate off-tumor toxicities or CRS by T cell engaging therapies. These data are being validated in vivo.

References


654

REAL WORLD INCIDENCE OF GRADE III AND HIGHER ADVERSE EFFECTS, EMERGENCY ROOM UTILIZATION AND HOSPITAL ADMISSIONS DURING TREATMENT WITH COMMONLY USED PD-1/PDL-1 TARGETING IMMUNE CHECK POINT INHIBITORS

1Nerea Lopetegui Lia, 2Syed Imran Jafri, 3Khalid Shalaby, 4Dimitrios Drekolias, 5James Vredenburgh, 1University of Connecticut, Hartford, CT, USA; 2University of Connecticut Health Center, Farmington, CT, USA; 3Smilow Cancer Hospital at St Francis Hosp, Hartford, CT, USA

Abstract 653 Figure 1 Representative flow cytometry experiment reporting SKM-1 target cell viability upon first stimulation with 10 nM HLA-A2 WT-1-TCB in the absence of dasatinib (left panel) and upon second stimulation with 10 nM HLA-A2 WT-1-TCB in the presence of 100 nM dasatinib (right panel)

Abstract 653 Figure 2 Real time killing (Incucyte) of red fluorescent A375 cells loaded with RMF peptides by 10 nM HLA-A2 WT-1-TCB (left panel) and of red fluorescent MKN45 cells by 1 nM CEA-TCB (right panel) in the presence of different dasatinib concentrations ranging from 100 nM to 0 nM. Mean of technical duplicates + SEM

Conclusions Taken together, we provide evidence for the use of dasatinib as a pharmacological on/off switch to mitigate off-tumor toxicities or CRS by T cell engaging therapies. These data are being validated in vivo.

REFERENCES


http://dx.doi.org/10.1136/jitc-2020-SITC2020.0653
